Covid-19 roundup: FDA authorizes Pfizer-BioNTech booster for 12-to-15-year-olds; Early results suggest antivirals may hold up against Omicron
Children between the ages of 12 and 15 years old are now eligible for a third dose of the Pfizer-BioNTech vaccine after the FDA authorized it Monday, as well as a third shot for those between 5 and 11 who are immunocompromised.
The FDA also shortened the time between the completion of a primary vaccine and a booster shot to five months for Pfizer’s jab, although Moderna’s booster interval remains at 6 months. The moves come as Omicron has ripped through the US, causing the number of positive cases to skyrocket.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.